National Institute for Health and Care Research
VC Fund
Whitehall, United Kingdom
National Institute for Health and Care Research is a VC fund in Whitehall focused on Health Care and Medical. The National Institute for Health Research (NIHR) is the research arm of the NHS. With an annual budget of over £1bn, it is the world’s second largest government funder of health research. It aims to maintain a health research system in which the NHS supports outstanding individuals, working in world class facilities, conducting leading edgeresearch focused on the needs of patients and the public.
- Total investments:
- 47
- Last investment:
- Lead investor:
- 77%
Last updated:
For AI agents: llms.txt
Industries National Institute for Health and Care Research invests in
Health CareMedicalMedical DeviceBiotechnologyHealth Diagnostics
Stages National Institute for Health and Care Research invests in
GrantPre-SeedFunding Round
Countries National Institute for Health and Care Research invests in
United KingdomUnited StatesCanadaSwedenAustria
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Erik Renz
|
|||
Sally Davies
|
|||
|
Stanleyxu phd
|
|||
Investment Focus
Industry
- Health Care 32 (68%)
- Medical 19 (40%)
- Medical Device 13 (28%)
- Biotechnology 12 (26%)
- Health Diagnostics 8 (17%)
Stage
- Grant 41 (87%)
- Pre-Seed 1 (2%)
- Funding Round 1 (2%)
Country
- United Kingdom 36 (77%)
- United States 3 (6%)
- Canada 2 (4%)
- Sweden 1 (2%)
- Austria 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Erik Renz
Information Analyst
|
Information Analyst | Total investments: 0 | Find email | |
Frank Nestle
Senior Investigator Emeritus
|
Senior Investigator Emeritus | Total investments: 0 | Find email | |
|
Sally Davies
Founder
|
Founder | Total investments: 0 | Find email | |
|
Stanleyxu phd
Head of Biostatistics
|
Head of Biostatistics | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BeCertain
|
BeCertain develops medical imaging software that applies artificial intelligence to support dental diagnosis. The company focuses on cloud-based clinical decision support tools that help dentists interpret 2D radiographs and 3D cone beam computed tomography scans. Its platform uses machine learning, statistical models, and image segmentation todetect dental pathologies, highlight critical anatomical structures, and assign confidence metrics to findings. The software is delivered through a browser-based, zero-installation interface designed to integrate with existing dental imaging workflows. BeCertain collaborates with oral health researchers and clinical practitioners to iteratively validate its algorithms and ensure defensible diagnostic outputs. The company targets dental practices, radiology services, and academic or hospital-based dental units seeking to standardize image assessment and reduce diagnostic variability. | $2.4M / Grant / Jul 16, 2026 | |
QV Bioelectronics
|
Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | Grant / Jan 21, 2026 | |
University of Liverpool
|
The University of Liverpool is one of the great centres of research, knowledge and innovation. Our pioneering reputation attracts students, experts and partners from around the world. Through our research, teaching and collaborations we seek to be life changing and world shaping.Exceptional minds1,300 leading researchers36,000 students177,000 alumni in 192 countries4,700 staffCountless partners worldwideLiverpool has been home to explorers and revolutionaries for over 800 years. Their pioneering spirit is alive in the city and inspires our university.Our university is everywhere, from our Chinese joint venture University to our Arctic research stations, American exchanges to the Internet home of our online programmes. | $2M / Grant / Jan 06, 2026 | |
Institute of Cancer Research
|
Institute of Cancer Research is a school in London. | $55M / Grant / Nov 21, 2025 | |
Sola Diagnostics
|
Product: Sola Diagnostics’ WID®-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. By analyzing DNA methylation markers from a simple vaginal swab, it offers high accuracy, reducing false positives and unnecessary surgeries. Target Audience: Designed for gynecologists andhealthcare providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that ensures earlier and more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain in 2025. UKCA Marking was registered in December 2024. So far, private equity investments totaling €2.4M have supported Sola's mission to revolutionize women’s health diagnostics. | $2.7M / Grant / Aug 01, 2025 | |
Bloom43
|
Bloom43 uses supraphysiological preconditioning to assist patients prepare and safeguard their bodies before surgery. Bloom43 uses unique technology to give preconditioning therapy, preventing surgical problems. | $1.6M / Grant / Jul 08, 2025 | |
Beyond Blood Diagnostics
|
Beyond Blood Diagnostics is an early-stage technology company in the healthcare industry. It focuses on developing at-home full blood count tests that provide rapid results without the need for traditional lab processing. This innovation aims to enhance precision medicine applications and improve health monitoring for chronic patients. The companyis leveraging recent technological advances to offer solutions that could transform patient care, particularly for those managing long-term health conditions. | Grant / Jun 25, 2025 | |
Linear Diagnostics
|
Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simplereagent | $1.4M / Grant / Jun 05, 2025 | |
Calla Lily Clinical Care
|
Calla Lily Clinical Care is a women’s health focused B-Corp that has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in fertility and pregnancy, where the company seeks to offer the world’s first drug-device combo product to prevent miscarriages, and for IVF luteal phase support. Callavid®can also deliver live biotherapeutics (LBPs) to reduce recurrent Bacterial Vaginosis, cutting antibiotic usage and reducing the spread of antimicrobial resistance (AMR). Further use-cases include HRT for menopause use cases, and effective medical sample collection (Lilyvid™ device) to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions. The company’s devices are built upon underlying technology named a TIME Magazine Best Invention of the Year. | $1.3M / Grant / Apr 03, 2025 | |
Yaqrit
|
Yaqrit, a clinical-stage company, is dedicated to pioneering innovative treatments for patients suffering from advanced liver disease, particularly those facing high risks of hospitalization and mortality. Its robust pipeline includes three cutting-edge therapeutics in Phase 2-3 development and two state-of-the-art medical devices. Yaqrit iscurrently preparing for Phase 3 clinical trials for its ammonia scavenger treatment, crucial for patients with hepatic conditions. | $2.8M / Grant / Mar 21, 2025 | |
| See all 47 investments → | |||
Co-Investors
Innovate UK
4 deals together
UK Research and Innovation
2 deals together
University of Liverpool
2 deals together
Imperial Enterprise Lab
1 deal together
National Institute for Health and Care Research
1 deal together
Prostate Cancer UK
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does National Institute for Health and Care Research invest in?
National Institute for Health and Care Research invests primarily in Health Care, Medical and Medical Device startups, most often at Grant and Pre-Seed stage. Most of the 47 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact National Institute for Health and Care Research?
Public channels for National Institute for Health and Care Research include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at National Institute for Health and Care Research?
The team at National Institute for Health and Care Research includes Erik Renz (Information Analyst), Frank Nestle (Senior Investigator Emeritus) and Sally Davies (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
